Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: 2022 RBC Capital Markets Global Healthcare Conference Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a fireside chat on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York.

Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a panel discussion on Thursday, April 7, 2022 at 11:00 a.m.

Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 3:30 p.m. ET in New York.

Arrakis Therapeutics today announced that James Mutamba, PhD, has joined the company as Chief Business Officer.

Arrakis Therapeutics today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Guggenheim Healthcare Talks Oncology Conference on Friday, February 11, 2022 at 10:00 a.m. ET.

Amgen will partner with Arrakis Therapeutics for an innovative collaboration to research and develop RNA degrader therapeutics.

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.

Arrakis Therapeutics today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 8:30 a.m. ET.

Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, announced today that it has appointed Amanda E. Hargrove, Ph.D., and Adrian Whitty, Ph.D., to its Scientific Advisory Board.